Note: This story was updated Jan. 24, 2024, to correct that Takeda is not supporting WVE-003’s development. Wave Sciences is the treatment’s sole developer; Takeda has a codevelopment and co-commercialization option. New data from a Phase 1/2 trial of WVE-003, a therapy targeting the mutant huntingtin protein in people…
Neurologists in the U.S. are optimistic about the potential for a new treatment for Huntington’s disease, but emphasize the need for therapies that halt nerve degeneration before symptom onset, according to a report by Spherix Global Insights. Most of the specialist physicians surveyed hoped for a gene therapy…
In 2023, Huntington’s Disease News brought you the latest in scientific breakthroughs and treatment developments related to Huntington’s disease. To recap what interested our readers most this year, here are the top 10 most-read articles, with a brief description of each. We look forward to serving as a…
People with Huntington’s disease have significantly higher levels of the proinflammatory molecule interleukin-6 (IL-6) and the anti-inflammatory molecule IL-10 in their blood relative to healthy people, according to a review study. The IL-6 difference was true for both pre-manifest patients — those carrying Huntington’s-causing mutations, but not yet having…
Rumi Scientific has joined with X-Chem to advance in early development a suppressor, or inhibitor, of bromodomain-containing protein 9 (BRD9) as a possible Huntington’s disease treatment. “BRD9 inhibition is a novel target for the treatment of HD [Huntington’s disease] identified by our proprietary high…
The Huntington’s Disease Society of America (HDSA) has awarded $898,194 in funding to support six research projects aiming to better understand and find more effective treatments for Huntington’s disease (HD). Grants were awarded through the HD Human Biology Project, HDSA’s largest research initiative supporting work focused…
Harness Therapeutics has secured an additional £4 million (about $5 million) in funding, which the U.K. biotech company plans to use to advance development of an experimental treatment for Huntington’s disease. “This further investment puts us in a strong position to address multiple neurodegenerative disease pathways, with an…
The contents of Ingrezza (valbenazine) can be taken from their capsules and crushed before being sprinkled on soft foods or given via a feeding tube to Huntington’s disease patients who have difficulty swallowing whole capsules, a preclinical study showed. A Neurocrine Biosciences’ oral therapy, Ingrezza…
Forms of mutant huntingtin (mHTT) protein that don’t clump initially drive early disease progression in people with Huntington’s disease, according to a study wherein patient-derived cells were transplanted into newborn mice. These soluble forms of mHTT were found to cause structural changes in the neurons producing them and to…
Nearly a year of treatment with Neurocrine Biosciences’ Ingrezza (valbenazine) leads to sustained reductions in uncontrolled movements known as chorea in adults with Huntington’s disease, according to interim data from a Phase 3 trial called KINECT-HD2. “The 50-week data from the ongoing KINECT-HD2 study provide insight on the…
Get regular updates to your inbox.